eligibility_summary
Include: Adults ≥18, ECOG 0–1, ≥3‑mo survival, contraception. Unresectable advanced/metastatic solid tumors after SOC failure/no SOC (multiple types), measurable disease, archival tumor if possible, adequate organ function, LVEF ≥50%. Exclude: recent tx/surgery/live vax, active brain mets, prior same‑target Tx, unresolved tox, bleeding/infection/immunosuppression, serious pulmonary (ILD/TB) or CV/CNS/QTc disease, uncontrolled effusion.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: MHB088C for Injection, an investigational antibody–drug conjugate (ADC), administered IV every 2 weeks. Mechanism of action: a tumor-targeting monoclonal antibody binds a tumor-associated surface antigen (specific antigen not disclosed), is internalized, and releases a linked cytotoxic payload inside the cancer cell, leading to targeted cell death while aiming to spare normal tissues. Study purpose: first-in-human dose escalation/expansion to define safety, PK, MTD/RP2D, and preliminary efficacy in advanced/metastatic solid tumors. Cells/pathways targeted: malignant solid-tumor cells that express the ADC’s target antigen, pathways include antigen-specific binding, receptor-mediated endocytosis/lysosomal processing, and intracellular payload-driven cytotoxicity within the tumor cell.